glp 1 agonist natural sources Unlocking the multifaceted roles of GLP-1: Physiological functions and therapeutic potential THE PCCA BLOG | GLP-1:

Professional tirzepatide therapy includes complete injection kit with syringes and free telehealth support

Available for both RF and RM licensing.

GLP-1RAs reduce events linked to atherogenic cardiovascular disease (especially ischemic stroke) and also renal outcomes (FLOW trial with semaglutide), with a limited effect on heart failure

The framework prioritised semaglutide and tirzepatide as first-line treatments, based on evidence of 15% weight loss and benefits in complications such as cardiovascular disease and sleep apnoea

Additionally, several key clinical trial readouts delivered compelling data across multiple indications, for example (see Figure 1): Semaglutide: STEP-HFpEF (functional benefits in HFpEF), STEP-9 (pain reduction in knee osteoarthritis), STEP-10 (reversion to normoglycaemia in pre-diabetic, obese patients), ESSENCE (resolution of MASH, improvement in fibrosis) Tirzepatide: SUMMIT (risk reduction in HFpEF outcomes